PALSONIFY Approved

Crinetics Pharmaceuticals (CRNX) received European Commission approval for PALSONIFY (paltusotine) on 27 member states and 3 EEA countries, making it the first once‑daily oral therapy for adult acromegaly in the EU. Approval was grounded in two Phase 3 studies that showed rapid onset, reliable biochemical control of IGF‑1, sustained efficacy and no serious adverse events. PALSONIFY also earned Orphan Drug Designation in the EU and will be commercially launched initially in Germany and Austria.